Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research)
https://doi.org/10.24060/2076-3093-2019-9-4-261-265
Abstract
Introduction. Mantle cell lymphoma is a rare type of B-cell non-Hodgkin lymphoma. According to statistics the incidence of this disorder amounts to 2-3 per 100,000 people; this is about 6% of all non-Hodgkin lymphomas. It has been established that various molecular genetic characteristics of mantle cell lymphoma patients may present opportunities for a patient-specific approach to the disease prognosis and treatment strategy.
Materials and methods. The paper presents a retrospective analysis of 45 mantle cell lymphoma patients treated at the GAUZ RKOD of the Ministry of Healthcare from 2015 until now. The data used in the analysis included clinical examination, lab panels, PET CT, tumour and bone marrow biopsy specimen cytology, histology and immunohistochemistry. We analysed the epidemiological data, the patients’ clinical presentation characteristics, treatment approaches, immediate and long-term outcomes.
Results and discussion. We have established that the pathological process most frequently involves bone marrow (44%) and spleen (41%). The MIPI scores distribution was as follows: high in 14 (30%), medium in 20 (45%), low in 11 (41%). Ki67 was recorded at under 30% in four cases, in others it amounted to over 30%. In 2015–2017 patients were treated with the R-CHOP protocol with the following support with rituximab. PFS averaged at 20 months, 8 (17%) of patients remain in lasting remission (since 2015). In 2017 the R-BAC (high dose cytarabine for SCT candidates) and R-B (for the elderly and comorbid patients) became protocols of first line. Since 2018 eight patients have undergone auto-SCT (at the first late recurrence) as a treatment consolidation stage. As of now 13 patients have been examined in federal centres for del17p and the TP53 mutation.
Conclusion. We have demonstrated the need for and the option of treatment depending on the results of molecular genetic testing of mantle cell lymphomas.
About the Authors
E. I. Kankumasheva
Republican Clinical Oncology Center
Russian Federation
Russian Federation
Kankumasheva Elza Ildarovna — Oncologist
73/1 Oktyabrya ave., Ufa, 450054
Ch. Kh. Valiakhmetova
Republican Clinical Oncology Center
Russian Federation
Russian Federation
Valiakhmetova Chulpan Khusaenovna — Candidate of Medical Sciences, Oncologist, Head of the Oncology Department of Antineoplastic Drug Therapy
73/1 Oktyabrya ave., Ufa, 450054
References
1. Poddubnaya I.V., Savchenko V.G. (eds.). Russian clinical practice guidelines for diagnosis and treatment of lymphoproliferative diseases. Moscow; 2018 (In Russ.).
2. Poddubnaya I.V., Savchenko V.G. (eds.). Diagnostic algorithms and protocols for treatment of diseases of the blood system. Vol. 1. Moscow; 2018 (In Russ.).
3. Mantle cell lymphoma in adults. Clinical practice guidelines. Moscow; 2018 (In Russ.).
4. Bernstein S.H., Epner E., Unger J.M., Leblanc M., Cebula E., Burack R., et al. A phase II multicenter trial of HyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24(6):1587–93. DOI: 10.1093/annonc/mdt070
5. Hilal T., Wang Z., Almader-Douglas D., Rosenthal A., Reeder C.B., Jain T. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. Am J Hematol. 2018;93(10):1220–6. DOI: 10.1002/ajh.25226
6. Lokvenc M., Kalinova M., Forsterova K., Klener P., Trneny M., Fronkova E., et al. Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma. Ann Hematol. 2018;97(3):467–74. DOI: 10.1007/s00277017-3210-8
7. Dreyling M., Campo E., Hermine O., Jerkeman M., Le Gouill S., Rule S., et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl. 4):62–71. DOI: 10.1093/annonc/mdx223
8. Rule S., Dreyling M., Goy A., Hess G., Auer R., Kahl B., et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–8. DOI: 10.1111/bjh.14870
9. Vorobyev V.I., Gemdzhian E.G., Dubrovin E.I., Nesterova E.S., Kaplanov K.D., Volodicheva E.M., et al. Risk-adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma. Therapeutic Archive. 2019;91(7):41–51 (In Russ.). DOI: 10.26442/00403660.2019.07.000322
10. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017.
11. Romaguera J.E., McLaughlin P.W. Mantle cell lymphoma. In: Lichtman M.A., Kipps T.J., Seligsohn U., et al. (eds) Williams hematology. New York: McGraw-Hill; 2014.
12. Dabaja B.S., Zelenetz A.D., Ng A.K., Tsang R.W., Qi S., Allen P.K., et al. Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Ann Oncol. 2017;28(9):2185–90. DOI: 10.1093/annonc/mdx334
13. Wang Y., Ma S. Risk factors for etiology and prognosis of mantle cell lymphoma. Expert Rev Hematol. 2014;7(2):233–43. DOI: 10.1586/17474086.2014.889561
14. Ruan J., Martin P., Christos P., Cerchietti L., Tam W., Shah B., et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132(19):2016–25. DOI: 10.1182/blood-2018-07-859769
15. Malcikova J., Pavlova S., Kozubik K.S., Pospisilova S. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. Hum Mutat. 2014;35(6):663–71. DOI: 10.1002/humu.22508
16. Vorobyov V.I., Lorie Yu.Yu., Mangasarova Ya.K., Kravchenko S.K., Kremenetskaya A.M. Potentialities of therapy for the mantle cell lymphoma relapses and resistant forms. Russian journal of hematology and transfusiology. 2011;(1):34–7 (In Russ.).
Review
For citations:
Kankumasheva E.I., Valiakhmetova Ch.Kh. Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research). Creative surgery and oncology. 2019;9(4):261-265. (In Russ.) https://doi.org/10.24060/2076-3093-2019-9-4-261-265
Views:
16141
Email this article 